Atlas Trials

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

Clinical trial NCT06918782 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06918782
Sponsor
The University of Hong Kong
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Cancer (NSCLC)
Start date
2025-05-01
Primary completion
2027-12-31
Enrollment
47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.